Researchers reported that TP53 mutations in urothelial carcinoma can drive CD8+ T cell exhaustion, contributing to therapy resistance through remodeling of the tumor immune microenvironment. The study, published in the British Journal of Cancer, describes a mechanism in which TP53-driven changes bias cytotoxic T cells toward an exhausted state. The work focuses on how tumor-intrinsic genetic alterations translate into broader immune dysfunction, linking a common mutation category in cancer to a specific immunologic failure mode. By connecting TP53 to the exhaustion phenotype, the findings point to new angles for immunotherapy selection and combination strategies in bladder cancer. For clinicians and translational teams, the key signal is that immune resistance may be partially explained by tumor genetics acting upstream of T cell functional decline, reinforcing the need for biomarker-led trial design.